FDA Approves Tregzi to Prevent Chronic GVHD in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory...
Treg therapy
Advertisement
FDA Approves Tregzi for Chronic GVHD Prevention in Blood Cancer
SILVER SPRING, Maryland, June 30, 2026 The U.S. Food and Drug Administration (FDA) has approved Tregzi, developed by Orca...
Cellenkos Secures FDA IND Clearance for CK0802 in GVHD Trial
HOUSTON, TEXAS, May 04, 2026 Cellenkos has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational...
TRexBio Advances TRB-061 Phase 1b Trial for Atopic Dermatitis
SOUTH SAN FRANCISCO, April 29, 2026 TRexBio, Inc. has announced that the first patient has been dosed in the...
Cellenkos Wins FDA Clearance for CK0801 Phase 2 Trial
HOUSTON, TEXAS, April 27, 2026 Cellenkos Inc. has received U.S. Food and Drug Administration (FDA) clearance to initiate a...
Advertisement
